Ces radiol. 2014, 68(1):22-29

PET/CT with 18F-fluorocholine in prostatic carcinoma, two years experienceOriginal article

Eva Ferdová1, Jiří Ferda1, Jan Baxa1, Milan Hora2, Ondřej Hes3, Jindřich Fínek4
1 Klinika zobrazovacích metod LF UK a FN, Plzeň
2 Urologická klinika LF UK a FN, Plzeň
3 Šiklův ústav patologické anatomie LF UK a FN, Plzeň
4 Klinika onkologie a radioterapie LF UK a FN, Plzeň

Aim: To evaluate our own experience with fluorocholine 18F-FCH-PET/CT in prostatic carcinoma.

Method: the analysis of the indications was performed in sample of 172 18F-FCH-PET/CT in 139 male patients, with mean age of 62.5 years in range 48-81 years. We evaluated number and site of metastases, the relation of PSA level in biochemical relaps with the presence of FCH accumulation in tumorous tissue and finally we correlate the findings of biopsy with results of PET/CT.

Results: IN patients with PSA level 2-5 ng/l we found in cases of biochemical relapse the accumulating tumorous tissue of local recurrence or metastases in 77.4%, in those patients with PSA level above 5 ng/l in 100% of cases. In comparison of biopsies with PET/CT we found sensitivity 96% and specificity 83.3%.

Conclusion: 18F-FCH-PET/CT is a valuable tool in evaluation of staging or restaging in patients with prostatic carcinoma.

Keywords: prostatic carcinoma, fluorocholine, PET/CT, PSA
Grants and funding:

Podpořeno projektem Ministerstva zdravotnictví ČR Koncepční rozvoj výzkumné instituce 00669806 - FN Plzeň a Programem rozvoje vědních oborů Karlovy Univerzity (projekt P36).

Accepted: January 30, 2014; Published: March 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferdová E, Ferda J, Baxa J, Hora M, Hes O, Fínek J. PET/CT with 18F-fluorocholine in prostatic carcinoma, two years experience. Ces radiol. 2014;68(1):22-29.
Download citation

References

  1. Schmid DT, John H, Zweifel R, Cservenyak T, Westera G, Goerres GW, von Schulthess GK, Hany TF. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005; 235(2): 623-628. Go to original source... Go to PubMed...
  2. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, Borsatti E, Drigo A, Trovò MG. [18F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33(12): 1387-1398. Go to original source... Go to PubMed...
  3. Kwee SA, Coel MN, Lim J. Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging. Ann Nucl Med 2012; 26(6): 501-507. Go to original source... Go to PubMed...
  4. Graute V, Jansen N, Ubleis C, Seitz M, Hartenbach M, Scherr MK, Thieme S, Cumming P, Klanke K, Tiling R, Bartenstein P, Hacker M. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging 2012; 39(2): 271-282. Go to original source... Go to PubMed...
  5. Kjölhede H, Ahlgren G, Almquist H, Liedberg F, Lyttkens K, Ohlsson T, Bratt O. Combined 18F-fluorocholine and 18F-fluoride positron emission tomography/computed tomography imaging for staging of high-risk prostate cancer. BJU Int 2012; 110(10): 1501-1506. Go to original source... Go to PubMed...
  6. Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 2013; 64(1): 106-117. Go to original source... Go to PubMed...
  7. Dundee PE, Hutton AC, Eden CG. [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 2011; 107(1): 158-159. Go to original source... Go to PubMed...
  8. Balogova S, Huchet V, Egrot C, Michaud L, Paycha F, Kerrou K, Montravers F, Cussenot O, Talbot JN. Effect of erythropoietin on bone marrow uptake of 18F-fluorocholine in prostate cancer: comparison with 18F-fluoride uptake. Clin Nucl Med 2013; 38(3): 200-202. Go to original source... Go to PubMed...
  9. Poulsen MH, Bouchelouche K, Gerke O, Petersen H, Svolgaard B, Marcussen N, Svolgaard N, Ogren M, Vach W, Høilund-Carlsen PF, Geertsen U, Walter S. [18F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 2010; 106(5): 639-643. Go to original source... Go to PubMed...
  10. Langsteger W, Balogova S, Huchet V, Beheshti M, Paycha F, Egrot C, Janetschek G, Loidl W, Nataf V, Kerrou K, Pascal O, Cussenot O, Talbot JN. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging 2011; 55(4): 448-457.
  11. Buchegger F, Garibotto V, Zilli T, Allainmat L, Jorcano S, Vees H, Rager O, Steiner C, Zaidi H, Seimbille Y, Ratib O, Miralbell R. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy. Eur J Nucl Med Mol Imaging 2014; 41(1): 68-78. Go to original source... Go to PubMed...
  12. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Loidl W, Broinger G, Stoiber F, Foglman I, Langsteger W. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008; 35(10): 1766-1774. Go to original source... Go to PubMed...
  13. Kwee SA, Wei H, Sesterhenn I, Yun D, Coel MN. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med 2006; 47(2): 262-269.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.